Since, cytokines like IL-6 and IL-1β are not primarily produced by CAR-T cells, targeting these cytokines by immunomodulatory agents may not completely prevent CRS and neurotoxicity; however, understanding mechanisms for myeloid cell activation during CAR-T cell therapy may help develop strategies that can prevent or reduce activation of myeloid cells. This evidence concerns the gene IL1B and congenital rubella syndrome.